Genmab A/S's (GMAB) Buy Rating Reiterated at HC Wainwright

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $50.00 target price on the stock. HC Wainwright's price objective points to a potential upside of 125.33% from the stock's current price.

A number of other equities research analysts have also weighed in on GMAB. BMO Capital Markets reissued an "outperform" rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Morgan Stanley reissued an "equal weight" rating and issued a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Finally, Redburn Atlantic assumed coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a "buy" rating on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus target price of $45.20.

Genmab A/S Stock Up 0.0 %

Shares of Genmab A/S stock traded up $0.01 during trading on Wednesday, reaching $22.19. The company's stock had a trading volume of 602,971 shares, compared to its average volume of 865,394. Genmab A/S has a 1-year low of $19.85 and a 1-year high of $32.56. The company has a 50-day simple moving average of $21.33 and a two-hundred day simple moving average of $24.28. The company has a market cap of $14.68 billion, a price-to-earnings ratio of 21.54, a P/E/G ratio of 0.63 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same period in the prior year, the business posted $0.47 EPS. As a group, analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after acquiring an additional 1,051 shares during the period. MML Investors Services LLC lifted its position in shares of Genmab A/S by 5.4% during the 3rd quarter. MML Investors Services LLC now owns 73,261 shares of the company's stock valued at $1,786,000 after buying an additional 3,785 shares in the last quarter. XTX Topco Ltd grew its stake in Genmab A/S by 116.4% in the 3rd quarter. XTX Topco Ltd now owns 25,429 shares of the company's stock valued at $620,000 after acquiring an additional 13,678 shares during the period. Two Sigma Advisers LP increased its holdings in Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock worth $14,996,000 after acquiring an additional 280,900 shares in the last quarter. Finally, Quantinno Capital Management LP increased its holdings in Genmab A/S by 56.8% in the 3rd quarter. Quantinno Capital Management LP now owns 24,207 shares of the company's stock worth $590,000 after acquiring an additional 8,766 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.